EGFR and non-small cell lung carcinoma: A previous prospective trial (RELAY) demonstrated that erlotinib combined with ramucirumab had a significantly longer median PFS than erlotinib combined with placebo in untreated advanced EGFR-mutated NSCLC patients (19.4 vs. 12.4 months).